WO2003029414A3 - INTRODUCTION OF THE WLDs GENE FOR PREVENTION OF AXONAL DEGENERATION IN NEUROLOGICAL DISEASES - Google Patents
INTRODUCTION OF THE WLDs GENE FOR PREVENTION OF AXONAL DEGENERATION IN NEUROLOGICAL DISEASES Download PDFInfo
- Publication number
- WO2003029414A3 WO2003029414A3 PCT/US2002/031078 US0231078W WO03029414A3 WO 2003029414 A3 WO2003029414 A3 WO 2003029414A3 US 0231078 W US0231078 W US 0231078W WO 03029414 A3 WO03029414 A3 WO 03029414A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- wlds
- gene
- introduction
- prevention
- neurological diseases
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2799/00—Uses of viruses
- C12N2799/02—Uses of viruses as vector
- C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
- C12N2799/022—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from an adenovirus
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biochemistry (AREA)
- Toxicology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US10/433,035 US20040127439A1 (en) | 2002-10-01 | 2002-10-01 | Introduction of the wld gene for prevention of axonal degeneration in neurological diseases |
CA002462632A CA2462632A1 (en) | 2001-10-01 | 2002-10-01 | Introduction of the wlds gene for prevention of axonal degeneration in neurological diseases |
EP02800391A EP1446014A4 (en) | 2001-10-01 | 2002-10-01 | INTRODUCTION OF THE WLDs GENE FOR PREVENTION OF AXONAL DEGENERATION IN NEUROLOGICAL DISEASES |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US32635401P | 2001-10-01 | 2001-10-01 | |
US60/326,354 | 2001-10-01 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2003029414A2 WO2003029414A2 (en) | 2003-04-10 |
WO2003029414A3 true WO2003029414A3 (en) | 2003-12-18 |
Family
ID=23271854
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2002/031078 WO2003029414A2 (en) | 2001-10-01 | 2002-10-01 | INTRODUCTION OF THE WLDs GENE FOR PREVENTION OF AXONAL DEGENERATION IN NEUROLOGICAL DISEASES |
Country Status (3)
Country | Link |
---|---|
EP (1) | EP1446014A4 (en) |
CA (1) | CA2462632A1 (en) |
WO (1) | WO2003029414A2 (en) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7429560B2 (en) * | 2002-09-25 | 2008-09-30 | Georgia Tech Research Corporation | Ketoamide inhibitors in chronic nerve disease |
GB201006961D0 (en) * | 2010-04-27 | 2010-06-09 | Babraham Inst | NMN modulator |
US11597917B2 (en) * | 2017-07-06 | 2023-03-07 | The Medical College Of Wisconsin, Inc. | In vitro and in vivo enrichment strategy targeting lymphocytes derived from vector transduced HSCs for therapy of disorders |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2401660A1 (en) * | 2000-03-02 | 2001-09-07 | Incyte Genomics, Inc. | Lipid metabolism enzymes |
-
2002
- 2002-10-01 WO PCT/US2002/031078 patent/WO2003029414A2/en not_active Application Discontinuation
- 2002-10-01 EP EP02800391A patent/EP1446014A4/en not_active Withdrawn
- 2002-10-01 CA CA002462632A patent/CA2462632A1/en not_active Abandoned
Non-Patent Citations (6)
Title |
---|
CONFORTI ET AL.: "A Ufd2/D4Cole1e chimeric protein and overexpression of Rbp7 in the slow Wallerian degeneration (WldS) mouse", PROC. NATL. ACAD. SCI. USA, vol. 97, no. 21, 10 October 2000 (2000-10-10), pages 11377 - 11382, XP002953257 * |
DATABASE GENBANK [online] 16 October 2000 (2000-10-16), "Mus musculus UFD2/D4COLE1E fusion protein mRNA", XP002953260, Database accession no. (AF260924) * |
FERNANDO ET AL.: "Characterization of the human homologue of a candidate gene for slow Wallerian degeneration", AMERICAN JOURNAL OF HUMAN GENETICS, vol. 67, no. SUPPLEMENT 2, October 2000 (2000-10-01), pages 178, XP002953261 * |
See also references of EP1446014A4 * |
WANG ET AL.: "Pathogenesis of axonal degeneration: parallels between Wallerian degeneration and vincristine neuropathy", J. OF NEUROPATHOLOGY AND EXP. NEUROLOGY, vol. 59, no. 7, July 2000 (2000-07-01), pages 599 - 606, XP002953258 * |
WANG ET AL.: "The gene for low Wallerian degeneration (WldS) is also protective against vincristine neuropathy", NEUROBIOLOGY OF DISEASE, vol. 8, 20 December 2000 (2000-12-20), pages 155 - 161, XP002953259 * |
Also Published As
Publication number | Publication date |
---|---|
WO2003029414A2 (en) | 2003-04-10 |
EP1446014A4 (en) | 2004-12-08 |
EP1446014A2 (en) | 2004-08-18 |
CA2462632A1 (en) | 2003-04-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2002060317A3 (en) | Compositions and methods for the therapy and diagnosis of pancreatic cancer | |
WO2002002624A3 (en) | B7-like molecules and uses thereof | |
WO2001070977A3 (en) | Fibroblast growth factor receptor-like molecules and uses thereof | |
EP1140840A4 (en) | -g(v)-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors | |
WO2002085857A3 (en) | Inhibition of raf kinase using quinolyl, isoquinolyl or pyridyl ureas | |
WO2005004794A3 (en) | Method of treating neurodegenerative disease | |
WO2001001748A3 (en) | Peptide compounds that bind her2 | |
WO2000073469A3 (en) | Protein kinases | |
WO2002089747A3 (en) | Compositions and methods for the therapy and diagnosis of prostate cancer | |
WO2002074156A3 (en) | Compositions and methods for the therapy and diagnosis of colon cancer | |
WO2003099771A3 (en) | Diaryl urea derivatives useful for the treatment of protein kinase dependent diseases | |
MXPA03002413A (en) | B7-like molecules and uses thereof. | |
WO2001072295A3 (en) | Compositions and methods for the therapy and diagnosis of lung cancer | |
WO2006060680A3 (en) | Mda-7 protein variants having antiproliferative activity | |
WO2002092001A3 (en) | Compositions and methods for the therapy and diagnosis of lung cancer | |
WO2001061007A3 (en) | Fibroblast growth factor-23 molecules and uses thereof | |
WO2002074237A3 (en) | Compositions and methods for the therapy and diagnosis of kidney cancer | |
WO2001079164A3 (en) | N-substituted dithiocarbamates for the treatment of biological disorders | |
WO2001068854A3 (en) | Fibroblast growth factor-like molecules and uses thereof | |
WO2000029846A3 (en) | COMPOSITIONS AND METHODS RELATING TO THE PEROXISOMAL PROLIFERATOR ACTIVATED RECEPTOR-α MEDIATED PATHWAY | |
WO2003037267A3 (en) | Compositions and methods for the therapy and diagnosis of lung cancer | |
WO2003024991A3 (en) | Tall-1 receptor molecules and uses thereof | |
WO2001077168A3 (en) | Compositions and methods for the therapy and diagnosis of lung cancer | |
WO2003029414A3 (en) | INTRODUCTION OF THE WLDs GENE FOR PREVENTION OF AXONAL DEGENERATION IN NEUROLOGICAL DISEASES | |
WO2002097046A3 (en) | B7 related protein-2 molecules and uses thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BY BZ CA CH CN CO CR CU CZ DE DM DZ EC EE ES FI GB GD GE GH HR HU ID IL IN IS JP KE KG KP KR LC LK LR LS LT LU LV MA MD MG MN MW MX MZ NO NZ OM PH PL PT RU SD SE SG SI SK SL TJ TM TN TR TZ UA UG US UZ VC VN YU ZA ZM |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): GH GM KE LS MW MZ SD SL SZ UG ZM ZW AM AZ BY KG KZ RU TJ TM AT BE BG CH CY CZ DK EE ES FI FR GB GR IE IT LU MC PT SE SK TR BF BJ CF CG CI GA GN GQ GW ML MR NE SN TD TG US |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
WWE | Wipo information: entry into national phase |
Ref document number: 10433035 Country of ref document: US |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2003532632 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2462632 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2002362458 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2002800391 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 2002800391 Country of ref document: EP |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 2002800391 Country of ref document: EP |